Full Text
PCN20 THE BUDGETARY IMPACT OF PEMETREXED PLUS CISPLATIN AS FIRST-LINE THERAPY FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)

Abstract

Authors

RC Wielage CE Muehlenbein AM Liepa SM Babineaux RW Klein LS Schwartzberg

Back to Volume 12, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×